Daniel Marson
A5089935579- Dementia and Cognitive Impairment Research
- Alzheimer's disease research and treatments
- Healthcare Decision-Making and Restraints
- Functional Brain Connectivity Studies
- Patient Dignity and Privacy
- Health Systems, Economic Evaluations, Quality of Life
- Aging, Elder Care, and Social Issues
- Elder Abuse and Neglect
- Mental Health and Psychiatry
- Genetic Associations and Epidemiology
- Bioinformatics and Genomic Networks
- Palliative Care and End-of-Life Issues
- Patient-Provider Communication in Healthcare
- Advanced Neuroimaging Techniques and Applications
- Neurological Disease Mechanisms and Treatments
- Traumatic Brain Injury Research
- Older Adults Driving Studies
- Frailty in Older Adults
- Ethics in medical practice
- Medical Malpractice and Liability Issues
- Parkinson's Disease Mechanisms and Treatments
- Ethics in Clinical Research
- Machine Learning in Bioinformatics
- Financial Literacy, Pension, Retirement Analysis
- Memory and Neural Mechanisms
University of Alabama at Birmingham
2015-2024
Alzheimer’s Disease Neuroimaging Initiative
1999-2024
San Francisco VA Medical Center
2024
University of California, San Francisco
2024
Mayo Clinic
2017-2022
Barrow Neurological Institute
2022
Boston University
2017-2018
Erasmus MC
2018
Institute for Neurodegenerative Disorders
2018
Framingham Heart Study
2018
Abstract Alzheimer’s Disease (AD) is a progressive neurodegenerative disease where biomarkers for based on pathophysiology may be able to provide objective measures diagnosis and staging. Neuroimaging scans acquired from MRI metabolism images obtained by FDG-PET in-vivo measurements of structure function (glucose metabolism) in living brain. It hypothesized that combining multiple different image modalities providing complementary information could help improve early AD. In this paper, we...
Abstract Alzheimer’s disease (AD) is a progressive neurodegenerative condition marked by decline in cognitive functions with no validated modifying treatment. It critical for timely treatment to detect AD its earlier stage before clinical manifestation. Mild impairment (MCI) an intermediate between cognitively normal older adults and AD. To predict conversion from MCI probable AD, we applied deep learning approach, multimodal recurrent neural network. We developed integrative framework that...
To estimate a regional progression pattern of amyloid deposition from cross-sectional amyloid-sensitive PET data and evaluate its potential for in vivo staging an individual's pathology.
To assess empirically the competency of patients with Alzheimer's disease (AD) to consent medical treatment under different legal standards (LSs).Comparison normal older subjects and AD on measures treatment.University center.Normal control (n = 15) probable 29 [15 mild 14 moderate AD]).Two specialized clinical vignettes were developed that test a subject's capacity five well-established LSs for this competency: LS1, evidencing choice; LS2, making reasonable LS3, appreciating consequences...
To assess financial capacity in patients with mild cognitive impairment (MCI) using a standardized psychometric measure.Participants were 21 cognitively normal older controls, amnestic MCI, and 22 AD. The Financial Capacity Instrument (FCI), measure consisting of 18 ability tests (tasks), 9 domains (activities), 2 total scores, was administered to participants along battery neuropsychological sensitive dementia. Group differences examined on the variables.Relative MCI group demonstrated...
To investigate financial capacity in patients with Alzheimer disease (AD) using a new theoretical model and prototype psychometric instrument.Cross-sectional comparisons of older control subjects (n=23) mild (n=30) moderate AD (n=20).Financial was measured the Financial Capacity Instrument, instrument that tests 14 tasks ability comprising 6 clinically relevant domains activity: basic monetary skills, conceptual knowledge, cash transactions, checkbook management, bank statement judgment.The...
A recently identified variant within the fat mass and obesity-associated (FTO) gene is carried by 46% of Western Europeans associated with an approximately 1.2 kg higher weight, on average, in adults 1 cm greater waist circumference. With >1 billion overweight 300 million obese persons worldwide, it crucial to understand implications carrying this very common allele for health our aging population. FTO highly expressed brain elevated body index (BMI) atrophy, but unknown how risk affects...
OBJECTIVE: To investigate the agreement of physician judgments capacity to consent treatment for normal and demented older adults. DESIGN: Subjects were individually administered a standardized interview. Physicians viewed videotapes these interviews made treatment. SETTING: University medical center. PARTICIPANTS: assessed competency (N = 45) 16 controls 29 patients with mild Alzheimer's disease (AD). Five center physicians experience assessing dementia recruited from specialties geriatric...
Regions of the temporal and parietal lobes are particularly damaged in Alzheimer's disease (AD), this leads to a predictable pattern brain atrophy. In vivo quantification subregional atrophy, such as changes cortical thickness or structure volume, could lead improved diagnosis better assessment neuroprotective effects therapy. Toward end, we have developed fast robust method for accurately quantifying cerebral structural several subcortical regions using serial MRI scans. 169 healthy...
To investigate 1-year change in financial capacity relation to conversion from amnestic mild cognitive impairment (MCI) dementia.Seventy-six cognitively healthy older controls, 25 patients with MCI who converted Alzheimer-type dementia during the study period (MCI converters), and 62 did not convert nonconverters) were administered Financial Capacity Instrument (FCI) at baseline follow-up. Performance on FCI domain global scores was compared within between groups using multivariate...
Background In primary prevention trials for Alzheimer disease, the inception cohort typically has normal or minimally impaired complex activities of daily living (ADL). ADL change during a trial could trigger detailed evaluation serve as an outcome measure. A brief, easily administered, and reliable rating scale would assist studies. Objectives To develop that allows self-rating completion by informants. Methods The Activities Daily Living-Prevention Instrument (ADL-PI) was developed,...
To examine associations between aggregate genetic risk and Alzheimer disease (AD) markers in stages preceding the clinical symptoms of dementia using data from 2 large observational cohort studies.We computed polygenic scores (PGRS) summary statistics International Genomics Alzheimer's Project genome-wide association study AD. Associations PGRS AD (cognitive decline, progression, hippocampus volume, β-amyloid) were assessed within older participants with dementia. volume additionally...
<b>Objectives: </b> To empirically assess the capacity of patients with amnestic mild cognitive impairment (MCI) to consent medical treatment under different standards (Ss). <b>Methods: Participants were 56 healthy controls, 60 MCI, and 31 Alzheimer disease (AD). Each participant was administered Capacity Consent Treatment Instrument (CCTI) a comprehensive neuropsychological battery. Group differences in performance on CCTI variables examined. In addition, status (capable, marginally...
<h3>Objective:</h3> To examine sex differences in the relationship between clinical symptoms related to Alzheimer disease (AD) (verbal memory deficits) and neurodegeneration (hippocampal volume/intracranial volume ratio [HpVR]) across AD stages. <h3>Methods:</h3> The sample included 379 healthy participants, 694 participants with amnestic mild cognitive impairment (aMCI), 235 dementia from Alzheimer9s Disease Neuroimaging Initiative who completed Rey Auditory Verbal Learning Test (RAVLT)....
To investigate the vascular contribution to longitudinal changes in Alzheimer disease (AD) biomarkers.The Alzheimer's Disease Neuroimaging Initiative is a clinic based, study with CSF, PET, and MRI biomarkers repeatedly measured participants normal cognition (NC), mild cognitive impairment (MCI), AD. Participants severe cerebrovascular risks were excluded. Cardiovascular risk scores white matter hyperintensities (WMHs) treated as surrogate markers for burden. Generalized estimating equations...
Financial capacity is a complex instrumental activity of daily living critical to independent functioning older adults and sensitive impairment in patients with amnestic mild cognitive (MCI) Alzheimer's disease (AD). However, little known about the neurocognitive basis financial dementia. We developed models cognitively healthy (n = 85) MCI 113) AD 43). All participants were administered Capacity Instrument (FCI) neuropsychological test battery. Univariate correlation multiple regression...
To study longitudinal relationships between type 2 diabetes mellitus (T2DM), cortical thickness, and cognitive function in older people with normal cognition, mild impairment, Alzheimer disease (AD).The sample was derived from the Alzheimer's Disease Neuroimaging Initiative cohort who underwent brain MRI tests annually for 5 years. Presence of T2DM based on fasting blood glucose ≥7.0mml/L or use glucose-lowering agents. We used latent growth curve modeling to explore T2DM, function,...
<h3>Objective:</h3> To examine the clinical and biomarker characteristics of patients with amyloid-negative Alzheimer disease (AD) mild cognitive impairment (MCI) from Alzheimer9s Disease Neuroimaging Initiative (ADNI), a prospective cohort study. <h3>Methods:</h3> We first investigated reliability florbetapir− PET in AD MCI using CSF-Aβ<sub>1–42</sub> as comparison amyloid measurement. then compared vs florbetapir+ respect to several AD-specific biomarkers, baseline longitudinal...
<h3>Objective:</h3> To assess the frequency and phenotype of hexanucleotide repeat expansions in <i>C9ORF72</i> a large cohort patients Dutch descent with familial (fALS) sporadic (sALS) amyotrophic lateral sclerosis (ALS), progressive muscular atrophy (PMA), primary (PLS). <h3>Methods:</h3> Included were 78 fALS, 1,422 sALS, 246 PMA, 110 PLS, 768 control subjects. Repeat determined by primed PCR. Familial aggregation dementia Parkinson disease (PD) was examined among ALS who carried...